Clinical trials: Stage III Melanoma
Melanoma Stage III, Melanoma Stage IV
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
Prospective evaluation of clinical outcomes in patients with resectable or metastatic BRAF+ melanoma treated with dabrafenib and trametinib in real practice
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Melanoma
- Trial name
- RATIONALE (NCT05171374)
- Testing
- Dabrafenib, Trametinib
- Where
- 15 sites in Russia
- Volunteers
- 500 people
- Sponsor
- MelanomaPRO, Russia
Malignant Melanoma
BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
This open-label, multicenter. single arm Phase I dose-escalation study with efficacy tail extension will evaluate the maximum tolerated dose/recommended dose, the safety and efficacy of vemurafenib (RO5185426) in pediatric…
- Trial name
- NCT01519323
- Testing
- vemurafenib
- Where
- 26 sites in United States, Australia and 8 more
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride in treating patients with metastatic or unresectable solid tumors.
- Conditions
- Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Breast Cancer
- Trial name
- NCT00089362
- Testing
- alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma Stage III, Melanoma Stage IV
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
The purpose of this study is to find out if the administration of Interleukin-2 concurrently with ipilimumab followed by Nivolumab will result in improved anti-cancer activity and if it is effective for advanced melanoma.
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Inoperable Disease
- Trial name
- NCT04562129
- Testing
- Interleukin-2, Ipilimumab, Nivolumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
This phase II clinical trial tests how well rigosertib plus pembrolizumab workings in treating patients with melanoma which cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site)…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Refractory Melanoma
- Trial name
- NCT05764395
- Testing
- Rigosertib, Pembrolizumab, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Unresected Stage IIIB to IVM1c Melanoma
Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma
The study is a phase 3b, multicenter, open-label, single-arm study designed to provide expanded access of Talimogene Laherparepvec for the treatment of subjects with unresected stage IIIB to IVM1c melanoma.
- Trial name
- NCT02297529
- Testing
- Talimogene Laherparepvec
- Where
- 3 sites in Switzerland
- Sponsor
- Amgen
Stages III Skin Melanoma, Stages II Skin Melanoma
Efficacy of Propranolol Treatment to Prevent Melanoma Progression
Melanoma's incidence is increasing worldwide. The efforts made in melanoma screening led to an earlier detection of the primary tumour and a better prognosis, but melanoma remains an aggressive cancer when it comes to its…
- Conditions
- Stages III Skin Melanoma, Stages II Skin Melanoma, Stage IB Skin Melanoma
- Trial name
- NCT01988831
- Testing
- Propranolol hydrochloride
- Where
- Switzerland
- Volunteers
- 450 people
- Sponsor
- University Hospital, Geneva
Melanoma
CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)
This is an extended use study for patients who have received 10 doses of CAVATAK™ in the VLA 007 trial. There may be patients who have benefitted from the study drug and who might benefit from further treatment.
- Trial name
- CALMext (NCT01636882)
- Testing
- CVA21
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Viralytics
Malignant Melanoma Stage II
Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma
Stage II patients with primary surgical treatment of cuMM are often at risk for recurrence of their disease. This risk may be reduced by adjuvant systemic treatment.
- Trial name
- NivoMela (NCT04309409)
- Testing
- Nivolumab
- Where
- 20 sites in Germany
- Volunteers
- 374 people
- Sponsor
- University Hospital, Essen
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Malignant Melanoma
Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab
Determine the safety, tolerability, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of ACY-241 in combination with ipilimumab and nivolumab in patients with unresectable Stage…
- Trial name
- NCT02935790
- Testing
- ACY-241, nivolumab, ipilimumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Celgene
Stage III Melanoma, Stage IV Melanoma
Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma
The purpose of this study is to assess the overall disease control rate of Ofatumumab wo/w Dacarbazine in subjects with American Joint Committee on Cancer (AJCC 2009) unresectable stage III or stage IV melanoma.
- Trial name
- NCT01376713
- Testing
- Ofatumumab, Ofatumumab plus Dacarbazine
- Where
- 2 sites in Austria
- Volunteers
- 10 people
- Sponsor
- Medical University of Vienna
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
This phase I/II trial studies the side effects and best dose of dabrafenib, trametinib, and navitoclax and to see how well they work in treating patients with BRAF mutant melanoma or solid tumors that has spread from where it…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm, Metastatic Melanoma
- Trial name
- NCT01989585
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 49 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
High Risk HLA-A2+ Melanoma, Metastatic Disease
Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
This study is based on the hypothesis that stimulation of the immune response against the tumor can help destroy residual tumor in melanoma patients with very high risk for disease recurrence and in patients with relatively low…
- Trial name
- NCT01861938
- Testing
- Melanoma vaccine modified to express HLA A2/4-1BB ligand
- Sponsor
- Hadassah Medical Organization
Melanoma
BO-112 With Pembrolizumab in Unresectable Malignant Melanoma
This is a phase 2, single arm, open label, adaptive design study to determine the preliminary anti-tumor activity and confirm the safety of IT BO-112 in combination with intravenous (IV) pembrolizumab.
- Trial name
- SPOTLIGHT203 (NCT04570332)
- Testing
- BO-112 plus pembrolizumab, Tissue Biopsies
- Where
- 19 sites in France, Spain
- Volunteers
- 42 people
- Sponsor
- Highlight Therapeutics
Melanoma
Intralesional PV-10 Chemoablation of Metastatic Melanoma
The objective of this study is to investigate the safety of intralesional (IL) PV-10 for the treatment of metastatic melanoma. This study will also include a preliminary assessment of response of treated and untreated lesions by…
- Trial name
- NCT00219843
- Testing
- PV-10 (rose bengal disodium, 10%)
- Where
- 2 sites in Australia
- Volunteers
- 20 people
- Sponsor
- Provectus Pharmaceuticals
Stage III Melanoma
Interferon Toxicities in Melanoma Treatment
The primary objective of this study is to quantify and compare the prevalence of adverse events (AEs) in patients with stage III melanoma before and after initiation of interferon (IFN) therapy in a real-world setting.
- Trial name
- ITMT (NCT02794636)
- Volunteers
- 436 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma
This study is being done to see if the investigators can help the immune system to work against melanoma. A dendritic cell is another type of white blood cell.
- Trial name
- NCT01456104
- Testing
- Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery
This phase Ib/II trial studies the side effects and best dose of propranolol hydrochloride when given together with pembrolizumab and how well they work in treating patients with stage IIIC-IV melanoma that cannot be removed by…
- Trial name
- NCT03384836
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Propranolol Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 47 people
- Sponsor
- Roswell Park Cancer Institute
Melanoma, Adjuvant Therapy
Nordic Adjuvant IFN Melanoma Trial
The aim of this study is to evaluate the effect of giving adjuvant treatment with intermediate doses of interferon-alpha2b to patients operated for high risk melanoma.
- Trial name
- NCT01259934
- Testing
- Interferon-alpha2b - 1 year, Interferon-alpha2b - 2 years
- Where
- Sweden
- Volunteers
- 855 people
- Sponsor
- Karolinska Institutet